Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Exclusion Criteria

• •1. History of another invasive malignancy that has not been in remission for at least 1 year. (Exceptions are nonmelanoma skin cancer, curatively treated localized prostate cancer, ductal carcinoma, and cervical carcinoma or a squamous intraepithelial lesion on PAP smear).
• •2. History of progressive multifocal leukoencephalopathy (PML).
• •3. Cerebral/meningeal disease related to the underlying malignancy, unless definitively treated.
• •4. Viral, bacterial, or fungal infection within 2 weeks prior to the first dose of treatment.
• •5. Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 4 weeks prior to first dose of study drug.
• •6. Females who are pregnant or breastfeeding.
• •7. Known allergy to any study drug or ingredient contained in the drug formulation of any of the study drugs.
• •8. Known to be positive for hepatitis B. Known to have active hepatitis C infection or on antiviral therapy for hepatitis C within the last 6 months.
• •9. Known to be positive for human immunodeficiency virus (HIV).
• •10. Patients with previous allogeneic stem cell transplant.
• •11. Previous treatment with brentuximab vedotin or bendamustine.
• •12. Intolerable toxicity to prior rituximab therapy.
• •13. Current therapy with other investigational agents.
• •14. Lung disease unrelated to underlying malignancy.
• •15. History of a stroke or transient ischemic attack, unstable angina, myocardial infarction, or cardiac symptoms within 6 months prior to the first dose of treatment.
• •16. Congestive heart failure.
• •17. Significant peripheral sensory or motor neuropathy at the start of the study.